Home > En > R and D > Publications > 2013



  • Alliot C, Audouin N, Bonraisin AC, Bossé V, Laizé J, Bourdeau C, Mokili BM, Michel N, Haddad F. 82Sr purification procedure using Chelex-100 resin. Appl Radiat Isot. 2013, 74, 56-60.
  • Denden I, Poineau F, Schlegel ML, Blain G, Solari PL, Rocques J, Czerwinski KR, Barbet J, Fattahi M. Behavior of heptavalent technetium in sulfuric acid under α-irradiation. Submitted.
  • Champion J, Sabatié-Gogova A, Bassal F, Ayed T, Alliot C, Galland N, Montavon G. Investigation of astatine(III) hydrolyzed species: experiments and relativistic calculations. J Phys Chem A. 2013, 117, 1983-1990.
  • Crumiere F, Vandenborre J, Essehli R, Blain G, Barbet J, Fattahi M. LET effects on the hydrogen production induced by the Cutler CS, Hennkens HM, Sisay N, Huclier-Markai S, Jurisson SS. Radiometals for combined imaging and therapy. Chem Rev. 2013, 113, 858-883.
  • Optimization of strontium-82 purification parameters using Chelex-100 resin. Alliot C, Audouin N, Bonraisin AC, Bossé V, Laizé J, Bourdeau C, Mokili BM, Michel N, Haddad F., Applied Radioation and Isotopes 74 (2013), 74, 56-60.
  • C.S. CUTLER, H. HENNEKENS, S. NEBIAT, S. HUCLIER-MARKAI and S.S. JURISSON. Combined Radionuclide Imaging and Therapy. Chem. Reviews, 2013, 113 (2), pp 858–883.
  • S.HUCLIER-MARKAI, C. ALLIOT, N. VARMENOT, C.S. CUTLER, J. BARBET. Alpha-Emitters Alpha-emitters for Immuno-Therapy: a review of recent developments from production to clinics. Curr. Topics in Med. Chem., 2012, 23, 2642-2654. (IF = 4.174)
  • ALLIOT, C., KERDJOUDJ, R., MOKILI, M., MICHEL, N., HADDAD, F., HUCLIER-MARKAI, S., BARBET, J. Processing of a 44m/44Sc generator for potential medical applications: production and chemistry aspects. Submitted to Appl. Rad., Isot., 2013
  • Production of copper-64 using deuteron beams and application to PET imaging projects such as Cu-ATSM to study hypoxia in tumor. Alliot C. et al, Programme RC-1146.2 - 2nd RCM on “Production and Utilization of Merging Positron Emitters for Medical Applications with a Focus on Copper-64 and Iodine-124” de l’IAEA, coordonateur M. Haji-Saeid.
  • Bodet-Milin, C., Ferrer, L., Pallardy, A., Eugène, T., Rauscher, A., Faivre-Chauvet, A., Barbet, J., Kraeber-Bodéré, F. (2013) Radioimmunotherapy of B-Cell Non-Hodgkin’s Lymphoma. Front Oncol. 3, 177.
  • Carlier, T., Eugène, T., Bodet-Milin, C., Garin, E., Ansquer, C., Rousseau, C., Ferrer, L., Barbet, J., Schoenahl, F., Kraeber-Bodéré, F. (2013) Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT. EJNMMI Res. 3, 11.
  • Chérel, M., Gouard, S., Gaschet, J., Saï-Maurel, C., Bruchertseifer, F., Morgenstern, A., Bourgeois, M., Gestin, J.F., Kraeber-Bodéré, F., Barbet, J., Moreau, P., Davodeau, F. (2013) 213Bi Radioimmunotherapy with an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple Myeloma. J. Nucl. Med. 54, 1597-1604.
  • Crumiere, F., Vandenborre, J., Essehli, R., Blain, G., Barbet, J., Fattahi, M. (2013) LET effects on the hydrogen production induced by the radiolysis of pure water. Radiation Phys Chem, 82, 74-79.
  • Frampas, E., Rousseau, C., Bodet-Milin, C., Barbet, J., Chatal, J.F., Kraeber-Bodéré, F. (2013) Improvement of radioimmunotherapy using pretargeting. Front Oncol. 3, 159.
  • Laffon, E., Bardiès, M., Barbet, J., Marthan, R. (2013) Calculating an estimate of tissue integrated activity in 18F-FDG PET imaging using one SUV value. EJNMMI Res. 3, 26.
  • Mauxion, T., Barbet, J., Suhard, J.M., Pouget, J.P., Poirot, M., Bardiès, M. (2013) Improved realism of hybrid mouse models may not be sufficient to generate reference dosimetric data. Med Phys. 40, 052501.
  • Rousseau, C., Kraeber-Bodéré, F., Barbet, J., Chatal, J.F. (2013) Pretargeted radioimmunotherapy: clinically more efficient than conventional radioimmunotherapy? Eur J Nucl Med Mol Imaging. 40, 1373-1376.


  • Chatal JF, Barbet J, Kraber-Bodéré F, Goldenberg DM. Medullary Thyroid Carcinoma. In: Nuclear Medicine Therapy: Principles and clinical applications. C. Aktolun et S.J. Goldsmith (eds.), Springer Verlag+Business Media, New-York, 2013.
  • Barbet, J., Chatal, J.F. Cyclotron-based Radiopharmaceuticals for Nuclear Medicine Therapy. In: Therapeutic Nuclear medicine. Editor: Richard Baum. Springer. In press.
  • Chatal, J.F., Kraeber-Bodéré, F., Goldenberg, D.M., Barbet, J. Medullary Thyroid carcinoma. In: Therapeutic Nuclear medicine. Editor: Richard Baum. Springer. In press.
  • Kraeber-Bodéré, F., Faivre-Chauvet, F., Bodet-Milin, C., Wegener, W.A., Chatal, J.F., Goldenberg, D.M. Fractionated Radioimmunotherapy of Non-Hodgkin Lymphoma with 90-Y-Labeled Anti-CD22 Antibody, Epratuzumab Tetraxetan. In: Therapeutic Nuclear medicine. Editor: Richard Baum. Springer. In press.
  • Köster U, Haddad F, Chouin N, Davodeau F, Chatal JF, Barbet J, Kraeber-Bodéré F. Encyclopedia of Nuclear Physics and its Applications- Chapter 17: Nuclear Medicine, Ed Willey. In press.


  • C. Duchemin, A. Guertin, V. Metivier, F. Haddad, N. Michel, Measurement of 230Pa and 186Re production cross sections induced by deuterons at ARRONAX facility, Proceedings of The 2013 International Conference on Applications of Nuclear Techniques (Crete, Greece, June 23-29 2013).
  • S. Huclier-Markai, R. Kerdjoudj, C. Alliot, A.C. Bonraisin, N. Michel, F. Haddad and J. Barbet. Optimization of reaction conditions for the radiolabeling of DOTA and DOTA-peptide with 44m/44Sc and experimental evidence of the feasibility of an in vivo PET generator.WIPR (submitted to Nucl Med Biol.)
  • M.Frindel et al, Radiolabeling of HTE1PA: a new monopicolinate cyclam derivative for Cu-64 phenotypic imaging. In vitro and in vivo stability studies in mice, (submitted to Nucl Med Biol.)